Dr. Ferris on Immunotherapy in Locally Advanced Head and Neck Cancer

Robert Ferris, MD, PhD
Published: Monday, Jun 19, 2017



Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses immunotherapy in patients with locally advanced head and neck cancer.

There has not been much improvement with treating patients who have HPV-negative head and neck cancer with radiation therapy, says Ferris.

In RTOG-3504, investigators are exploring whether adding an immunotherapy on top of concurrent chemoradiation improves survival for patients with intermediate- and high-risk disease in the locally advanced setting.
 


Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses immunotherapy in patients with locally advanced head and neck cancer.

There has not been much improvement with treating patients who have HPV-negative head and neck cancer with radiation therapy, says Ferris.

In RTOG-3504, investigators are exploring whether adding an immunotherapy on top of concurrent chemoradiation improves survival for patients with intermediate- and high-risk disease in the locally advanced setting.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x